Clinical Cancer Research:上海药物所发现阿司匹林抗肿瘤转移的作用机制

2017-09-21 黄洵 上海药物所

阿司匹林是经典的非甾体类抗炎药,从发现至今已沿用百年。在过去的三十年间,大量流行病学、临床试验、动物实验研究发现,长期使用阿司匹林能显着降低肿瘤发生率、延缓恶性肿瘤病程、减少肿瘤远端转移发生风险以及降低肿瘤死亡率,但其抗肿瘤作用机制仍不明确。


阿司匹林是经典的非甾体类抗炎药,从发现至今已沿用百年。在过去的三十年间,大量流行病学、临床试验、动物实验研究发现,长期使用阿司匹林能显着降低肿瘤发生率、延缓恶性肿瘤病程、减少肿瘤远端转移发生风险以及降低肿瘤死亡率,但其抗肿瘤作用机制仍不明确。

为剖析阿司匹林的抗肿瘤转移的作用靶点,上海药物所研究人员从药物-蛋白质组学研究出发,首次发现乙酰肝素酶为阿司匹林潜在的抗肿瘤转移作用靶点。乙酰肝素酶是哺乳动物体内唯一能够识别HSPG多糖侧链-HS结构的内源性β-葡萄糖醛酸酯酶,与肿瘤的转移密切相关。研究表明,阿司匹林通过结合于调节乙酰肝素酶的酶活关键氨基酸Glu225位,抑制酶活功能,调控相关信号通路,从而抑制肿瘤的血管新生和转移。该研究为全面认识阿司匹林抗肿瘤作用机制提供了新的理论基础。同时,考虑到目前处于研发前沿的乙酰肝素酶抑制剂均为肝素类似物,而相关的小分子抑制剂研发工作无突破性进展,该研究也为乙酰肝素酶小分子抑制剂的研发提供了新的方向。

研究成果于2017年7月14日在线发表于Clinical Cancer Research。研究工作得到了中科院战略性先导科技专项,国家自然科学基金,山东海洋科学联合基金等有关项目的资助。

原文出处:
Xiao-Yang Dai, Juan Yan, Xuhong Fu, et al., Aspirin inhibits cancer metastasis and angiogenesis via targeting heparanase,Clin Cancer Res.,2017.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1972174, encodeId=3b1e19e217474, content=<a href='/topic/show?id=1212199e12e' target=_blank style='color:#2F92EE;'>#上海药物所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19971, encryptionId=1212199e12e, topicName=上海药物所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Thu Feb 08 02:54:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247445, encodeId=2ee224e445b1, content=学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcVAydhtcpjiaxLrZD7Eb5YnKPgf7ypGpfyl7FflFyAenvQLbib6T0LPXIhXo9SPNPXYYFFJbEgykztwJ0HQ61I3F9GxIVKWsgQ/0, createdBy=f38d2052407, createdName=周周人, createdTime=Mon Sep 25 06:24:57 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291638, encodeId=fc3e129163827, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat Sep 23 02:54:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507625, encodeId=f34b150e6256a, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Sat Sep 23 02:54:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557770, encodeId=a146155e77097, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Sat Sep 23 02:54:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246388, encodeId=5851246388af, content=是很好的学习材料.不错.以后会多学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Sep 21 20:06:05 CST 2017, time=2017-09-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1972174, encodeId=3b1e19e217474, content=<a href='/topic/show?id=1212199e12e' target=_blank style='color:#2F92EE;'>#上海药物所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19971, encryptionId=1212199e12e, topicName=上海药物所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Thu Feb 08 02:54:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247445, encodeId=2ee224e445b1, content=学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcVAydhtcpjiaxLrZD7Eb5YnKPgf7ypGpfyl7FflFyAenvQLbib6T0LPXIhXo9SPNPXYYFFJbEgykztwJ0HQ61I3F9GxIVKWsgQ/0, createdBy=f38d2052407, createdName=周周人, createdTime=Mon Sep 25 06:24:57 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291638, encodeId=fc3e129163827, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat Sep 23 02:54:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507625, encodeId=f34b150e6256a, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Sat Sep 23 02:54:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557770, encodeId=a146155e77097, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Sat Sep 23 02:54:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246388, encodeId=5851246388af, content=是很好的学习材料.不错.以后会多学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Sep 21 20:06:05 CST 2017, time=2017-09-21, status=1, ipAttribution=)]
    2017-09-25 周周人

    学习.

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1972174, encodeId=3b1e19e217474, content=<a href='/topic/show?id=1212199e12e' target=_blank style='color:#2F92EE;'>#上海药物所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19971, encryptionId=1212199e12e, topicName=上海药物所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Thu Feb 08 02:54:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247445, encodeId=2ee224e445b1, content=学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcVAydhtcpjiaxLrZD7Eb5YnKPgf7ypGpfyl7FflFyAenvQLbib6T0LPXIhXo9SPNPXYYFFJbEgykztwJ0HQ61I3F9GxIVKWsgQ/0, createdBy=f38d2052407, createdName=周周人, createdTime=Mon Sep 25 06:24:57 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291638, encodeId=fc3e129163827, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat Sep 23 02:54:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507625, encodeId=f34b150e6256a, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Sat Sep 23 02:54:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557770, encodeId=a146155e77097, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Sat Sep 23 02:54:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246388, encodeId=5851246388af, content=是很好的学习材料.不错.以后会多学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Sep 21 20:06:05 CST 2017, time=2017-09-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1972174, encodeId=3b1e19e217474, content=<a href='/topic/show?id=1212199e12e' target=_blank style='color:#2F92EE;'>#上海药物所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19971, encryptionId=1212199e12e, topicName=上海药物所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Thu Feb 08 02:54:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247445, encodeId=2ee224e445b1, content=学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcVAydhtcpjiaxLrZD7Eb5YnKPgf7ypGpfyl7FflFyAenvQLbib6T0LPXIhXo9SPNPXYYFFJbEgykztwJ0HQ61I3F9GxIVKWsgQ/0, createdBy=f38d2052407, createdName=周周人, createdTime=Mon Sep 25 06:24:57 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291638, encodeId=fc3e129163827, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat Sep 23 02:54:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507625, encodeId=f34b150e6256a, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Sat Sep 23 02:54:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557770, encodeId=a146155e77097, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Sat Sep 23 02:54:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246388, encodeId=5851246388af, content=是很好的学习材料.不错.以后会多学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Sep 21 20:06:05 CST 2017, time=2017-09-21, status=1, ipAttribution=)]
    2017-09-23 zll0628
  5. [GetPortalCommentsPageByObjectIdResponse(id=1972174, encodeId=3b1e19e217474, content=<a href='/topic/show?id=1212199e12e' target=_blank style='color:#2F92EE;'>#上海药物所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19971, encryptionId=1212199e12e, topicName=上海药物所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Thu Feb 08 02:54:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247445, encodeId=2ee224e445b1, content=学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcVAydhtcpjiaxLrZD7Eb5YnKPgf7ypGpfyl7FflFyAenvQLbib6T0LPXIhXo9SPNPXYYFFJbEgykztwJ0HQ61I3F9GxIVKWsgQ/0, createdBy=f38d2052407, createdName=周周人, createdTime=Mon Sep 25 06:24:57 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291638, encodeId=fc3e129163827, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat Sep 23 02:54:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507625, encodeId=f34b150e6256a, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Sat Sep 23 02:54:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557770, encodeId=a146155e77097, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Sat Sep 23 02:54:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246388, encodeId=5851246388af, content=是很好的学习材料.不错.以后会多学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Sep 21 20:06:05 CST 2017, time=2017-09-21, status=1, ipAttribution=)]
    2017-09-23 yangshch
  6. [GetPortalCommentsPageByObjectIdResponse(id=1972174, encodeId=3b1e19e217474, content=<a href='/topic/show?id=1212199e12e' target=_blank style='color:#2F92EE;'>#上海药物所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19971, encryptionId=1212199e12e, topicName=上海药物所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Thu Feb 08 02:54:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247445, encodeId=2ee224e445b1, content=学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcVAydhtcpjiaxLrZD7Eb5YnKPgf7ypGpfyl7FflFyAenvQLbib6T0LPXIhXo9SPNPXYYFFJbEgykztwJ0HQ61I3F9GxIVKWsgQ/0, createdBy=f38d2052407, createdName=周周人, createdTime=Mon Sep 25 06:24:57 CST 2017, time=2017-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291638, encodeId=fc3e129163827, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat Sep 23 02:54:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507625, encodeId=f34b150e6256a, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Sat Sep 23 02:54:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557770, encodeId=a146155e77097, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Sat Sep 23 02:54:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246388, encodeId=5851246388af, content=是很好的学习材料.不错.以后会多学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Sep 21 20:06:05 CST 2017, time=2017-09-21, status=1, ipAttribution=)]
    2017-09-21 李东泽

    是很好的学习材料.不错.以后会多学习.

    0

相关资讯

服用阿司匹林要知道七点

目前,为预防各种缺血性心脑血管病的发生,临床上有许多中老年人都需要长期服用小剂量阿司匹林。但是,一项涉及6.8万名患者的调查研究发现:超过1/10的患者服用阿司匹林不当。

J Royal Soci Inter:阿司匹林预防癌症让人又爱又恨

研究人员报道称,每日使用阿司匹林可能能够降低结肠癌的风险,也可能使疾病更难治疗。他们提醒称,这项基于数学建模的新发现,如果在统计学和实验室中确认,将意味着使用阿司匹林抵御结肠癌可能会付出高昂的成本。

今天,庆祝阿司匹林120周年!

众所周知,阿司匹林作为百年传奇经典药物,在医学界乃至全世界都有着举足轻重的地位。在一百多年中,前司匹林像世界巨星医院具有“头条体质”,一不小心就多次登上了国际新闻头条。1950年,阿司匹林作为最畅销的止痛药,获吉尼斯世界记录。1969年,拜耳阿司匹林作为小工具包的一部分,伴随阿波罗11号的宇航员登月。1980年,美国国家科学院宣称阿司匹林有效的缓解头痛,是最好的止痛药。1972年,英国药理学家约翰

Lancet:≥75岁者使用阿司匹林严重出血风险升高2倍,或许都应使用PPI?

近日,发表在Lancet上的一项观察性研究称,≥75岁老年人使用阿司匹林与致残或致命性出血明显增加有关。与不足75岁者相比,≥75岁者发生严重出血风险升高2倍,死亡风险升高4倍。

PLOS ONE:警惕:阿司匹林样镇痛药可能导致严重耳聋!

赖斯大学的一项研究发现,阿司匹林样药物二氟尼柳阻止了prestin的作用,它是听力所需的关键蛋白质。

阿司匹林又双叒叕有新用途了!

“神药”阿司匹林又双叒叕有新用途了!英国贝尔法斯特女王大学的研究者发现,阿司匹林能逆转蛀牙的影响,使补牙需求降低。